ONC insider ownership: who sold, why, and what they still hold

What stands out

Xiaobin Wu sold $7.4M of stock with no disclosed trading plan. The filings don't state a reason.Largest such sale, Nov 12, 2025

Selling picked up in the last 90 days: officers and directors sold 659K shares, against an average of 156K per 90 days earlier in the period. Most of it was John Oyler (582K shares in the last 90 days) and Xiaodong Wang (69K shares in the last 90 days); 99.7% of these sales were under disclosed plans.John Oyler: largest recent sale, Aug 10, 2026 · Xiaodong Wang: largest recent sale, Sep 28, 2026

A share of stake is shown for 0 of the 11 officers and directors who sold. 16 are left out

Left out: John Oyler, Xiaodong Wang, Lai Wang, Xiaobin Wu, Chan Lee, Aaron Rosenberg, Titus Ball, Anthony Hooper, Corazon Sanders, Alessandro Riva, Margaret Dugan, Qingqing Yi, Olivier Brandicourt, Shalini Sharp, Charles Sawyers and Elizabeth Mooney (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

John Oyler

Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$328M99% planned, 1% to cover taxes

Xiaodong Wang

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$24.7MDisclosed plan

Xiaobin Wu

President and COO

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$8.8M1% planned, 15% to cover taxes 84% no plan disclosed

Chan Lee

SVP, General Counsel

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.6M82% planned, 18% to cover taxes

Lai Wang

President, Global Head of R&D

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$1.2MTo cover taxes

All 11 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

Sep 30, 2026Chan Lee sold 1.1K shares ($418K) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Chan Lee SVP, General Counsel	1,115	$375.00	n/a	n/a	Sep 30, 2026	Oct 2, 2026

Sep 28, 2026Xiaodong Wang sold 31K shares ($11.3M) under a disclosed trading plan. 31K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Xiaodong Wang Director	31,028	$364.79	n/a	n/a	Sep 28, 2026	Sep 30, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Outside holders, reported separately

BAKER BROS. ADVISORS LP sold $262K in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the BeOne Medicines Ltd. CEO selling stock?

Yes. John Oyler sold 1.02M shares ($328M) in the past 12 months, 99% of it under a trading plan disclosed in the filings.

Why are BeOne Medicines Ltd. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 96% of sales by value ran under 10b5-1 trading plans disclosed in the filings, 2% were to cover taxes and 2% had no disclosed plan. A trading plan schedules sales in advance.

Are any BeOne Medicines Ltd. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold11 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
John Oyler Chief Executive Officer, Director	$328M 1.02M shares	Not confirmed share of stake is being verified. Why	99% under a disclosed plan, 1% to cover taxes
Xiaodong Wang Director	$24.7M 69K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Xiaobin Wu President and COO	$8.8M 25K shares	Not confirmed share of stake is being verified. Why	1% under a disclosed plan, 15% to cover taxes 84% no plan disclosed
Chan Lee SVP, General Counsel	$4.6M 14K shares	Not confirmed share of stake is being verified. Why	82% under a disclosed plan, 18% to cover taxes
Lai Wang President, Global Head of R&D	$1.2M 4.4K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Corazon Sanders Director	$961K 2.8K shares	Not confirmed share of stake is being verified. Why	7% to cover taxes 93% no plan disclosed
Aaron Rosenberg Chief Financial Officer	$524K 1.8K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Titus Ball Principal Accounting Officer	$127K 437 shares	Not confirmed share of stake is being verified. Why	To cover taxes
Margaret Dugan Director	$66K 212 shares	Not confirmed share of stake is being verified. Why	To cover taxes
Alessandro Riva Director	$66K 212 shares	Not confirmed share of stake is being verified. Why	To cover taxes
Qingqing Yi Director	$66K 235 shares	Not confirmed share of stake is being verified. Why	To cover taxes

Outside holder, reported separately: BAKER BROS. ADVISORS LP (an outside shareholder, not part of management). Sold $262K (11K shares) from May 22, 2026 to May 22, 2026. Latest filing

The full ownership picture0 of 16 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

John Oyler

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for John Oyler are complete.

Chief Executive Officer, Director

n/a

−1.02M

n/a

Vesting, gifts, unvested awards and holding lines for John Oyler

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for John Oyler are complete; balances and unit counts will be added when the check is finished.

−1.01Mgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
7	$0.50	Jul 19, 2025	$3K
1	$7.70	Sep 26, 2027	$367
9	$13.05	Apr 29, 2028	$3K
923,975	$12.23	Jun 4, 2034	$335M
348,374	$20.26	Jun 9, 2035	$124M
344,669	$20.81	Jun 10, 2036	$122M

Estimate: options held × ($375.00 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Xiaodong Wang

Director

n/a

−69K

n/a

Vesting, gifts, unvested awards and holding lines for Xiaodong Wang

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Xiaodong Wang are complete; balances and unit counts will be added when the check is finished.

−424Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
7	$0.50	Jun 29, 2025	$3K
7	$0.50	Jul 19, 2025	$3K
806,715	$2.84	Nov 15, 2026	$300M
410,657	$12.23	Jun 4, 2034	$149M
185,796	$20.26	Jun 9, 2035	$65.9M
193,492	$20.81	Jun 10, 2036	$68.5M

Estimate: options held × ($375.00 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Lai Wang

President, Global Head of R&D

n/a

−4.4K

n/a

Vesting, gifts, unvested awards and holding lines for Lai Wang

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Lai Wang are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
318,253	$12.23	Jun 4, 2034	$115M
162,565	$20.26	Jun 9, 2035	$57.7M
229,775	$20.81	Jun 10, 2036	$81.4M

Estimate: options held × ($375.00 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Xiaobin Wu

President and COO

n/a

−25K

n/a

Vesting, gifts, unvested awards and holding lines for Xiaobin Wu

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Xiaobin Wu are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2	$13.05	Apr 29, 2028	$724
309,881	$11.98	Jun 21, 2032	$112M
358,046	$12.23	Jun 4, 2034	$130M
232,245	$20.26	Jun 9, 2035	$82.4M
229,775	$20.81	Jun 10, 2036	$81.4M

Estimate: options held × ($375.00 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Chan Lee

SVP, General Counsel

n/a

−14K

n/a

Vesting, gifts, unvested awards and holding lines for Chan Lee

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Chan Lee are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
57,369	$16.41	Jun 14, 2033	$20.6M
88,582	$12.23	Jun 4, 2034	$32.1M
88,244	$20.26	Jun 9, 2035	$31.3M
87,308	$20.81	Jun 10, 2036	$30.9M

Estimate: options held × ($375.00 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Aaron Rosenberg

Chief Financial Officer

n/a

−1.8K

n/a

Vesting, gifts, unvested awards and holding lines for Aaron Rosenberg

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Aaron Rosenberg are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
220,987	$14.06	Aug 8, 2034	$79.8M
119,873	$20.26	Jun 9, 2035	$42.5M
137,865	$20.81	Jun 10, 2036	$48.8M

Estimate: options held × ($375.00 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Titus Ball

Principal Accounting Officer

n/a

−437

n/a

Vesting, gifts, unvested awards and holding lines for Titus Ball

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Titus Ball are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,677	$15.97	Aug 30, 2033	$5.3M
15,340	$12.23	Jun 4, 2034	$5.6M

Estimate: options held × ($375.00 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Anthony Hooper

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Anthony Hooper are complete.

Director

n/a

Vesting, gifts, unvested awards and holding lines for Anthony Hooper

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Anthony Hooper are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
34,151	$12.23	Jun 4, 2034	$12.4M
22,750	$18.19	May 20, 2035	$8.1M

Estimate: options held × ($375.00 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Corazon Sanders

Director

n/a

−2.8K

n/a

Vesting, gifts, unvested awards and holding lines for Corazon Sanders

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Corazon Sanders are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
22,750	$18.19	May 20, 2035	$8.1M

Estimate: options held × ($375.00 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Alessandro Riva

Director

n/a

−212

n/a

Vesting, gifts, unvested awards and holding lines for Alessandro Riva

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Alessandro Riva are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
34,151	$12.23	Jun 4, 2034	$12.4M
22,750	$18.19	May 20, 2035	$8.1M

Estimate: options held × ($375.00 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Margaret Dugan

Director

n/a

−212

n/a

Vesting, gifts, unvested awards and holding lines for Margaret Dugan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Margaret Dugan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
34,151	$12.23	Jun 4, 2034	$12.4M
22,750	$18.19	May 20, 2035	$8.1M

Estimate: options held × ($375.00 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Qingqing Yi

Director

n/a

−235

n/a

Vesting, gifts, unvested awards and holding lines for Qingqing Yi

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Qingqing Yi are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
34,151	$12.23	Jun 4, 2034	$12.4M
22,750	$18.19	May 20, 2035	$8.1M

Estimate: options held × ($375.00 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Olivier Brandicourt

Director

n/a

Vesting, gifts, unvested awards and holding lines for Olivier Brandicourt

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Olivier Brandicourt are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
27,794	$12.74	Feb 28, 2034	$10.1M
34,151	$12.23	Jun 4, 2034	$12.4M
22,750	$18.19	May 20, 2035	$8.1M

Estimate: options held × ($375.00 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Shalini Sharp

Director

n/a

Vesting, gifts, unvested awards and holding lines for Shalini Sharp

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Shalini Sharp are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
17,238	$17.27	Sep 29, 2034	$6.2M
22,750	$18.19	May 20, 2035	$8.1M

Estimate: options held × ($375.00 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Charles Sawyers

Director

n/a

Vesting, gifts, unvested awards and holding lines for Charles Sawyers

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Charles Sawyers are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Elizabeth Mooney

Director

n/a

Vesting, gifts, unvested awards and holding lines for Elizabeth Mooney

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Elizabeth Mooney are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Holdings and share of stake for BeOne Medicines Ltd. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$369M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $369M across 1,136,849 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $353M · 96%

The lighter segment is sales with no plan disclosed in the filing ($16.2M), including tax-related sales outside a plan.

No plan disclosed · $8.3M

Sales with no 10b5-1 plan and no tax reference in the filing. $7.4M of it is Xiaobin Wu. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Xiaobin Wu, Nov 12, 2025

Taxes

$8.0M of sales (2.2%) cite tax obligations in their footnotes. Example: Titus Ball, Sep 1, 2026

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
John Oyler Chief Executive Officer, Director	1.02M	$328M	99%	89%	Dec 15, 2025 to Aug 12, 2026
Xiaodong Wang Director	69K	$24.7M	100%	7%	Sep 8, 2026 to Sep 28, 2026
Xiaobin Wu President and COO	25K	$8.8M	1%	2%	Nov 12, 2025 to Aug 25, 2026
Chan Lee SVP, General Counsel	14K	$4.6M	82%	1%	Nov 12, 2025 to Sep 30, 2026
Lai Wang President, Global Head of R&D	4.4K	$1.2M	0%	0.3%	Jun 8, 2026 to Jun 23, 2026
Corazon Sanders Director	2.8K	$961K	0%	0.3%	Nov 26, 2025 to May 22, 2026
Aaron Rosenberg Chief Financial Officer	1.8K	$524K	0%	0.1%	Jun 11, 2026 to Aug 3, 2026
Titus Ball Principal Accounting Officer	437	$127K	0%	0.0%	Jun 8, 2026 to Sep 1, 2026
Margaret Dugan Director	212	$66K	0%	0.0%	May 22, 2026 to May 22, 2026
Alessandro Riva Director	212	$66K	0%	0.0%	May 22, 2026 to May 22, 2026
Qingqing Yi Director	235	$66K	0%	0.0%	Jun 1, 2026 to Jun 1, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$8.6M	$348K	$0	$8.3M
Dec 2025	$30.9M	$30.9M	$0	$0
Jan 2026	$220K	$220K	$0	$0
Feb 2026	$580K	$580K	$0	$0
Mar 2026	$102K	$102K	$0	$0
Apr 2026	$103K	$103K	$0	$0
May 2026	$300K	$103K	$197K	$0
Jun 2026	$7.0M	$0	$7.0M	$0
Jul 2026	$208M	$208M	$338K	$0
Aug 2026	$87.9M	$87.5M	$362K	$0
Sep 2026	$25.1M	$25.1M	$47K	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

More than usual: about 2x the 5-year average. 11 insiders sold; the average is 7 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	1.14M	11	$369M
Oct 13, 2025 1 year earlier	971K	8	$245M
Oct 13, 2024 2 years earlier	149K	6	$25.6M
Oct 14, 2023 3 years earlier	162K	7	$36.6M
Oct 14, 2022 4 years earlier	105K	6	$21.7M
Oct 14, 2021 5 years earlier	1.45M	8	$194M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty16 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for BeOne Medicines Ltd. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology573 filings on record, 71 filed in the 12-month period, and how we read them

All 573 Forms 3, 4 and 5 on record for BeOne Medicines Ltd. (SEC CIK 1651308), filed from Feb 2, 2016 to Oct 2, 2026; 71 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages. 2 filings were left out because BeOne Medicines Ltd. filed them as an owner of another company's stock.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (19)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
HHLR ADVISORS, LTD.	Dec 4, 2024	196,185,108 shares, last reported balance as of Dec 2, 2024
Julia Wang	Jul 3, 2024	426,595 shares, last reported balance as of Jul 1, 2024
Donald Glazer	Jun 7, 2024	2,756,633 shares, last reported balance as of Jun 5, 2024
Thomas Malley	Jun 20, 2023	76,696 shares, last reported balance as of Jun 15, 2023
Jane Huang	Dec 16, 2021	160,055 shares, last reported balance as of Dec 14, 2021
AMGEN INC	Sep 13, 2021	255,193,647 shares, last reported balance as of Sep 10, 2021
Howard Liang	Jun 30, 2021	1,553,149 shares, last reported balance as of Jun 28, 2021
Timothy Chen	Jun 21, 2021	7,800 shares, last reported balance as of Jun 16, 2021
Jingshyh su	Jun 21, 2021	7,800 shares, last reported balance as of Jun 16, 2021
Amy Peterson	Dec 19, 2018	194,569 shares, last reported balance as of Dec 18, 2018
Ji Li	Mar 2, 2018	475,000 shares, last reported balance as of Feb 28, 2018
Ke Tang	Apr 21, 2017	No balance on record
Jianxin Yang	Jul 15, 2016	200,000 shares, last reported balance as of Feb 2, 2016
Wendy Yan	Jul 15, 2016	No balance on record
Merck & Co., Inc.	Feb 10, 2016	7,942,314 shares, last reported balance as of Feb 8, 2016
CB Biotech Investment Ltd	Feb 9, 2016	19,601,138 shares, last reported balance as of Feb 8, 2016
RuiRong Yuan	Feb 9, 2016	130,000 shares, last reported balance as of Feb 8, 2016
Ranjeev Krishana		No balance on record
Michael Goller		No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

BeOne Medicines Ltd. insiders sold $369M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the BeOne Medicines Ltd. CEO selling stock?

Why are BeOne Medicines Ltd. insiders selling?

Are any BeOne Medicines Ltd. insiders buying?

The evidence

No plan disclosed · $8.3M

Taxes

Sales by month